Healthcare Companies By Ps Ratio

Price To Sales
Price To SalesEfficiencyMarket RiskExp Return
1VRDN Viridian Therapeutics
4.08 K
(0.11)
 4.11 
(0.47)
2NWBO Northwest Biotherapeutics
858.96
(0.02)
 3.65 
(0.06)
3SEPN Septerna, Common Stock
586.6
(0.23)
 8.80 
(2.02)
4UPB Upstream Bio,
184.56
(0.25)
 6.32 
(1.56)
5NEUP Neuphoria Therapeutics
145.56
 0.09 
 17.31 
 1.61 
6GELS Gelteq Limited Ordinary
111.96
 0.06 
 19.10 
 1.20 
7AVR Anteris Technologies Global
101.59
 0.11 
 4.13 
 0.45 
8BSGM BioSig Technologies, Common
90.04
(0.07)
 9.74 
(0.66)
9SILO Silo Pharma
77.69
 0.10 
 9.25 
 0.92 
10EUDA EUDA Health Holdings
36.55
 0.00 
 6.49 
(0.02)
11MGRX Mangoceuticals, Common Stock
26.98
 0.17 
 6.04 
 1.03 
12LLY Eli Lilly and
17.98
 0.14 
 1.82 
 0.25 
13BBNX Beta Bionics, Common
17.82
(0.46)
 2.44 
(1.13)
14NTRA Natera Inc
13.44
(0.02)
 2.44 
(0.05)
15CBLL CeriBell,
12.79
(0.04)
 3.43 
(0.14)
16IDXX IDEXX Laboratories
9.6
 0.08 
 2.07 
 0.16 
17BSX Boston Scientific Corp
8.88
 0.19 
 1.06 
 0.20 
18WGS GeneDx Holdings Corp
8.81
 0.08 
 8.16 
 0.69 
19TLX Telix Pharmaceuticals Limited
8.09
 0.10 
 3.23 
 0.33 
20EW Edwards Lifesciences Corp
7.75
 0.02 
 1.81 
 0.03 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries. The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.